Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A +/- Hydrodistension for OAB
NCT02995967Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Symptom Bother (OAB-q bother subscale) at 12 weeks. Started Nov 2016; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02995967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995967.